Answers are grounded in this paper and cite their sources.
Introduction Hemolytic uremic syndrome (HUS) has long been classified as a diarrhea-positive and diarrhea-negative entity, particularly in children, because it was thought that prognostically and management-wise the disease behaved differently. It was used to be a gesture that diarrheal episodes in HUS would have a better outcome rather than a presentation with no diarrhea. Therefore, the thrombotic microangiopathy (TMA) with the presentation of hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI), a syndromic characteristic, need a fair management strategy. However, over the years, continuing research and extensive studies had effectively identified the nature of the disease, and newer classification has evolved, and atypical HUS (aHUS), a new distinction of complement-mediated disease with management plan with an agent such as eculizumab, has come up. When diagnosing HUS, diarrhea used to be considered a significant factor. However, while it is not always present, several studies have indicated that aHUS may be associated with gastrointestinal symptoms, including diarrhea and vomiting. Therefore, diarrhea does not rule out a potential case of aHUS and should not be the sole focus of diagnosis. Hemolytic Uremic Syndrome HUS is a leading cause of AKI in children. It is associated with the clinical triad of thrombocytopenia, anemia, and AKI.[1,2] Across the world, the majority of HUS follows gastrointestinal infection with Shiga toxin-producing organisms, chiefly Escherichia coli, that is, Shiga toxin-producing E. coli (STEC) that accounts for 85%–95% of cases in children. Approximately 5% of cases are associated with invasive infections by Streptococcus pneumoniae and known as S. pneumoniae–HUS. On the other hand, aHUS, genetic dysregulation of the alternative complement pathway, accounts for 5%–10%.[1,2] The overall incidence of HUS is 1–2 cases per 100,000 per year, with most cases attributed to STEC-HUS.[3] In children presenting with E. coli enterocolitis, approximately 15% will progress to the development of HUS, with younger age, leukocytosis, and female gender increasing the chances of progression[1] Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome TMA is characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) with varying degrees of organ damage in the setting of normal international normalized ratio and activated partial thromboplastin time.[3,4] aHUS, characterized by a triad of thrombocytopenia, AKI, and MAHA, is a rare form of TMA caused by dysregulation of the alternative pathway (AP).[5] aHUS associated with factor H (FH) antibodies is more common, accounting for ~50% of pediatric patients.[6] Genetic variants in complement regulatory proteins account for 50%–60% of all aHUS cases, with approximately 30%–50% having no known identifiable mutation.[7] The overall incidence of aHUS, also termed complement-mediated TMA, is estimated at 2 per 1,000,000 individuals. In the United States, 70% of children experience their first episode before age two, with boys and girls being equally affected when the onset occurs during childhood.[1,8,9] Determining the underlying etiology can be a major challenge but is important for directed therapy. Classification of HUS International HUS group classifies HUS into: (1) infection-associated HUS, (2) pneumococcal HUS, (3) HUS secondary to coexisting conditions, (4) cobalamin C defect, and (5) aHUS [Table 1].[10] While the clinical presentation is similar in aHUS and STEC, it differs by etiology [Figure 1]. For typical HUS, Shiga toxin is produced by E. coli 0157:H7 or S. dysenteriae. When the patients are negative for Shiga toxin, other etiologies such as genetic or sporadic causes must be investigated. The aHUS is distinguished from typical or STEC by the absence of STEC infections. Also, it is distinguished from thrombotic thrombocytopenic purpura by a normal level of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity.[2,11]Table 1: Classification of hemolytic uremic syndromeFigure 1: Atypical hemolytic uremic syndrome triggers. Novel developing triggers are highlighted in green. HIV = human immunodeficiency virus, SARS-COV-2 = severe acute respiratory syndrome coronavirus 2[12],[13]Clinical Manifestations TMA is characterized by thrombocytopenia and MAHA. aHUS can induce organ damage due to ischemia downstream of occluded blood vessels.[14,15] So that extrarenal complications can present in aHUS patients and often affect the gastrointestinal system (intestinal bleeding and pancreatitis), central nervous system (seizures, cortical blindness, encephalopathy, and drowsiness), pulmonary system (pulmonary hemorrhage), cardiovascular system (myocardial infarction, heart failure, and cardiomyopathy), and the skeletal system (rhabdomyolysis) [Table 2].[10]Table 2: Clinical manifestations of aHUS based on organ system[11],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25],[26]Gastrointestinal Presentation of aHUS Age cannot be a distinguishing feature of typical and atypical HUS as the majority of aHUS patients present between 1 and 7 years old, which is also the most common age for presentations of children with typical HUS.[27] In a European cohort, in 74% of cases, gastrointestinal symptoms have been a triggering event. Diarrhea was seen in 11 patients of the cohort of 45. Other events such as vomiting as gastrointestinal symptoms and respiratory tract infection were there. The important observations showed that 74% of patients had gastrointestinal symptoms and 25% presented with diarrhea. This depicts that diarrhea could be a presenting feature of aHUS in children. Therefore, this makes it difficult to differentiate between typical and atypical HUS in children. Therefore, the treatment adequacy is often compromised. A Turkish study in aHUS in children showed 69 patients (of 146) had diarrhea at presentation comprising almost 48%. From 26 pediatric nephrology centers, 53 of the 146 patients (30.3%) were less than 2 years old at presentation.[16] In a Portuguese study of five aHUS patients, three patients had a triggering feature of gastrointestinal symptoms.[28] Auto-complement factor H (CFH) antibodies may be responsible for pediatric patients at greater risk for gastrointestinal complications, and more than 80% of patients with anti-CFH antibodies can have gastrointestinal symptoms.[29] Similarly, in 56% of pediatric aHUS cohort, Roman-Ortiz et al.[30] observed vomiting and abdominal pain. Gastrointestinal symptoms were also observed by Web et al.[31] in a 16-year-old male with aHUS, which resolved after 7 weeks of treatment. Though individuals with aHUS do not present with aggressive diarrhea that characterizes the onset of STEC-HUS but diarrhea could be a presentation of aHUS in 30%–50% of patients.[32] Therefore, the absence of bloody diarrhea, negative stool culture for Shiga toxin-producing E. coli or S. dysenteriae, aggressive course, accumulation of fluid in the body, and hematuria with proteinuria and hypoalbuminemia might carry a possibility of aHUS. aHUS has been a presenting feature of diarrhea as a trigger in 24% of cases.[33] Evaluation of HUS and aHUS Rapid diagnosis and prompt management of HUS are essential to limit irreversible renal damage. Patients with suspected HUS require urgent evaluation by a specialist to initiate appropriate treatment. History and clinical evaluation rule out the common secondary causes of HUS including Shiga toxin-producing E. coli or S. dysenteriae (STEC) and coexisting conditions/diseases including drugs, transplantations, systemic lupus erythematosus, antiphospholipid syndrome, scleroderma, pregnancy, and cobalamin deficiency.[32,33,34,35] aHUS is characterized by endothelial damage and microvascular thrombosis. About 40% of patients have a pathogenic variant in genes encoding regulatory proteins or factors of the alternative complement pathway (factor H, factor I, CD46, factor B, complement 3, and thrombomodulin [THBD]) or rearrangements of genes encoding factor H (FH)-related proteins.[36,37] The diagnosis of aHUS is made by the presence of TMA with normal ADAMTS13 activity without secondary causes. Due to rarity, the Kidney Disease: Improving Global Outcomes did not advise routine evaluation for ADAMTS13 activity in children with HUS.[38] For evaluation in patients with aHUS: (i) complement 3; (ii) test for anti-factor H (FH) antibodies; (iii) flow cytometry for expression of membrane cofactor protein (MCP and CD46) on neutrophils; and (iv) sequencing of CFH, CFI, complement factor B, complement 3, CD46, THBD, and diacylglycerol kinase-ε. Blood specimens for complement 3 and anti-FH antibodies should be drawn before instituting therapy. Therefore, molecular assay helps in all probabilities in establishing the diagnosis, clarifying underlying pathophysiology guide treatment decision and prognosis. Patients with anti-FH antibody–associated HUS do not routinely require screening for genetic variants. Genetic screening is advised with (i) early age of onset, (ii) relapsing course, (iii) family history of HUS, (iv) illness that is refractory to therapy with plasma exchange, and (v) before renal transplantation.[10,39,40] Tables 3 and 4 inherited defects of the AP are the chief cause of aHUS in Europe and North America. The standard of care for patients is complement blockade with eculizumab, a humanized anti-C5 antibody.[44] Eculizumab is expensive and unavailable in developing countries, so that plasma exchange or plasma infusions remain the chief option for patients with aHUS, especially those with genetic defects in the complement pathway.[10,44]Table 3: Diagnosis of HUS in presence of the following[10],[41],[42]Table 4: Evaluation of patients with hemolytic uremic syndrome[10]In conclusion, the traditional diagnosis with the presentation of diarrhea does not necessarily make the diagnosis of typical HUS. As diarrhea is a triggering factor in a significant number of cases of aHUS. Efforts should always be there in doing the molecular analysis and the complement for reaching the diagnosis, and in the end, it is a diagnosis of exclusion. So that the initiation of proper management strategy including eculizumab and others could be formulated and the prognosis could be predicted. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Chowdhury Yakub Jamal (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: